$AMRN After reading the Stifel conference transcript I’m confident Amarin will be a winner for any long term holder. One interesting callout is Amarin has drawn a line in the sand for generic sales, anything more than 10% of US market share and Amarin will bring down the hammer and act. This 10% market share target is a very big disconnect from some analysts which have estimates as high has 90% for generics. If Amarin can keep generics at bay with only a 10% marketshare we will be back in the $20+ range in 2021.
  • 22